Higher dose of schistosomiasis drug shows promise for toddlers

NCT ID NCT03640377

Completed Disease control Sponsor: Rhode Island Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two doses (40 vs 80 mg/kg) of praziquantel in 354 children aged 1-4 with schistosomiasis in Uganda. The goal was to find the best dose to cure the infection and improve growth and anemia. Currently, praziquantel is not approved for children under 4, and this trial aims to fill that gap.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: praziquantel
What this could lead to: If successful, this could lead to better dosing guidelines for young children with schistosomiasis, improving cure rates and reducing disease burden.
What could go wrong: This is a Phase II trial with 354 children, so results are still preliminary. Higher doses may cause more side effects, and findings may not apply to all regions or parasite types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHISTOSOMA JAPONICUM INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Schistosoma japonicum infectious disease Schistosoma mansoni infectious disease schistosomiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHISTOSOMA JAPONICUM INFECTION SCHISTOSOMIASIS SCHISTOSOMIASIS MANSONI

Contacts and locations

Locations

London School of Tropical Hygiene and Medicine

London, United Kingdom
Medical Research Council

Entebbe, 3FC6+Q3C,, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.